Senior Vice President, Global Therapeutic Asset Lead Dysport & IPN10200

About Ipsen:

Ipsen is a mid-sized global biopharmaceutical company with a focus on transformative medicines in three therapeutic areas: Oncology Rare Disease and Neuroscience. Supported by nearly 100 years of development experience with global hubs in the U.S. France and the U.K we tackle areas of high unmet medical need through research and innovation.

Our passionate teams in more than 40 countries are focused on what matters and endeavor every day to bring medicines to patients in 88 countries. We build a workplace that champions human-centric leadership and fosters a culture of collaboration excellence and impact. At Ipsen every individual is empowered to be their true selves grow and thrive alongside the companys success. Join us on our journey towards sustainable growth creating real impact on patients and society!

For more information visit us at follow our latest news on LinkedIn and Instagram.

The Senior Vice President Global Assets Lead Dysport Therapeutic & IPN10200 Tx is the single point of accountability for Ipsens therapeutic neuromodulator portfolio integrating leadership of:
Dysport Therapeutics (Tx) a globally established brand in spasticity cervical dystonia and potentially chronic migraine.
IPN10200 Therapeutics (Tx) a nextgeneration neurotoxin currently in Phase II.

This newly created role reflects Ipsens transition to a unified enterpriselevel therapeutic leadership model. The VP sets the longterm strategy drives execution across development evidence access operations and commercialization and ensures value maximisation across both assets while providing highvisibility leadership to the Executive Leadership Team.

The role combines two distinct accountabilities under a single senior leader:

Dysport Therapeutic (Tx) Global Asset Lead:
Accountable for the full strategic clinical medical access operational and commercial trajectory of a global commercialised asset with active lifecycle expansion including the major planned indication expansion in migraine.

IPN10200 Therapeutic (Tx) Global Asset Lead:
Accountable for building a differentiated insightdriven early global brand strategy and shaping the future value of an innovative Phase II molecule ensuring the foundation for a bestinclass global launch as the asset advances to latestage development.

This is the first role within Ipsens AssetCentric Model to combine leadership of two therapeutic assets reflecting the strategic importance and interdependency of Dysport and IPN10200.

Through unified and disciplined leadership the VP ensures singlepoint accountability for strategy performance and governance across both assets connecting strategic direction planning and execution seamlessly across R&D Medical Commercial Market Access Tech Ops and Regions/Affiliates.

Main Responsibilities & Technical Competencies

Strategic Leadership of the Therapeutic Neuroscience Portfolio
Define and lead the unified therapeutic strategy for Ipsens neuromodulator portfolio ensuring a coherent longterm vision across Dysport and IPN10200.
Own the Integrated Asset Strategy (IASP) for both assets including TPP/TVP CDP IEGP lifecycle management roadmap country prioritization and business case development.
Drive enterpriselevel scenario planning to optimize indication sequencing launch sequencing competitive positioning and longterm value creation.

Dysport Therapeutics (Tx) Global Asset Leadership
Lead the endtoend strategic clinical medical access operational and commercial trajectory of Dysport ensuring sustained performance in established indications and successful expansion into new ones such as migraine.
Oversee lifecycle management evidence generation pricing and access strategy and geographic expansion to support longterm competitive differentiation.
Ensure strong crossfunctional execution and alignment with regional and affiliate teams to maximize inmarket performance and patient impact.

IPN10200 Therapeutics (Tx) Global Development & Early Brand Leadership
Lead the development strategy for IPN10200 through Phase II and into pivotal development ensuring scientific regulatory clinical and commercial readiness.
Shape early global brand positioning and differentiation ensuring development CMC regulatory and evidence strategies support future value claims and launch success.
Integrate commercial competitive and patient insights early to influence critical decisions including clinical design target label launch sequencing and access strategy.

CrossFunctional Leadership & Operating Model Excellence
Lead highperforming crossfunctional Asset Teams ensuring clarity of roles disciplined execution and adherence to ACM principles.
Oversee functional SubTeams (Clinical Development Evidence Generation Target Value Team CMC/TechOps Commercial/Brand Safety Regulatory) to deliver integrated planning and execution.
Ensure robust risk management scenario planning KPI tracking and crossfunctional decisionmaking across both development and commercial phases.

Governance & DecisionMaking Excellence
Lead preparation and presentation of governance packages for PSC PC PFR and GBOC ensuring decisionready materials and strategic clarity.
Serve as the single point of accountability for escalating risks resolving crossfunctional issues and enabling timely enterprise decisions.
Ensure consistency quality and accuracy of strategic updates business cases milestone deliverables and scenario analyses.

External Leadership & Ecosystem Engagement
Represent Ipsen to global scientific experts investigators payers patient organizations and industry partners strengthening Ipsens leadership in neuromodulation.
Shape the external scientific and therapeutic narrative for Dysport and IPN10200 to ensure credibility differentiation and alignment with the evolving competitive landscape.
Provide insight and guidance on external innovation and business development opportunities relevant to the future neuroscience portfolio.

People & Culture Leadership
Build inspire and develop highperforming global teams in a matrix environment fostering collaboration and crossfunctional accountability.
Promote a culture grounded in enterprise mindset patient centricity and highquality decisionmaking.
Develop future leadership talent and ensure strong succession planning across development medical commercial and operational functions.

Knowledge & Experience

Capabilities

• Strategic thinker able to connect scientific medical and commercial insights into coherent plans
• Strong analytical forecasting and scenariomodelling ability
• Exceptional communication and influencing skills
• Demonstrated ability to operate effectively in complex matrixed global environments
• High ethical standards and commitment to patient value

Knowledge & Experience (essential):

• 20 years of progressive experience across strategy commercial and operational leadership roles years in pharma/biotech with extensive global leadership experience.

• Demonstrated leadership of large globally scaled brands ideally including responsibility for assets with >$1B annual revenue or with clear billiondollar growth potential.

• Experience leading assets in highprevalence / massmarket diseases. Experience in highprevalence fastevolving or highly competitive therapeutic areas (e.g. migraine immunology diabetes) an advantage.

• Proven ability to shape global market environments (guidelines treatment paradigms payer positioning) for diseases with large patient populations and complex care pathways.

• Track record influencing latestage development and leading global launches in competitive dynamic or fastevolving markets.

• Proven record in leading global commercial brands with active lifecycle management

• Significant experience engaging global KOLs major markets (US/EU5/China) and payers in disease areas requiring broad physician adoption and competitive differentiation.

• Global launch leadership across multiple major markets (US EU5 China) including payer negotiations diverse HTA landscapes and complex crossregional coordination.

• Proven track record of delivering results across local (in-market) regional and global settings with a strong understanding of market dynamics and cross-functional alignment.

• Demonstrated ability to shape clinical development strategy (TPP/TVP alignment endpoint strategy comparator selection regulatory interactions) informed by commercial access and patient insights.

• Deep expertise in strategic planning organizational transformation operational excellence and business execution.

• Strong business and commercial acumen with experience driving growth initiatives and leading cross-functional programs in matrix organizations.

Education / Certifications (essential):

• Advanced degree in Business Economics Life Sciences or related discipline.

• MBA or equivalent business qualification preferred

Education / Certifications (preferred):

• Additional certifications in project management transformation leadership or change management are a plus

Language(s) (essential):

• English (fluent spoken and written)

Language(s) (preferred):

• Additional languages e.g. French or other a benefit